Velcan Holdings: Share buyback program - weekly statement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Luxembourg, 28th October 2024
SHARES REPURCHASE PROGRAMME
Authorized by the shareholders’ meeting held on 29th June 2021
Implemented upon the decision of the Board of Directors dated 2nd January 2024,
DISCLOSURE OF PURCHASES
EFFECTED FROM 18th OCTOBER 2024 TO 25th OCTOBER 2024
Market: Euro MTF, Luxembourg
Type of shares: ordinary shares ISIN FR0010245803
| Trading date | Number of shares purchased | Purchase price per share | Total amount of purchases | Purpose | Market |
| 18/10/2024 | 95 | 14.50 € | 1 337.50 € | Cancellation or free shares coverage | Euro MTF Luxembourg |
| 24/10/2024 | 286 | 14.50 € | 4 147.00 € | Cancellation or free shares coverage | Euro MTF Luxembourg |
| 25/10/2024 | 50 | 14.50 € | 725.00 € | Cancellation or free shares coverage | Euro MTF Luxembourg |
Repurchase programme’s full description dated 15th January 2024 is available on Velcan Holdings’ website
* * *
Regulatory information available on www.velcan.lu
Investor Relations Contact [email protected]
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
- Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026
- Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
